Class Effect: Dapagliflozin Reduces Cardiovascular and Kidney Events
The sodium-dependent glucose co-transporter (SGLT-2) inhibitors are the newest class of oral agents in the armoury of the physician to combat type 2 diabetes mellitus (T2DM). The significant reduction in cardiovascular outcomes with all three SGLT2- inhibitors is now well documented (1-3), as is the reduction in chronic kidney disease (CKD) outcomes with canagliflozin (4). The effect of another SGLT-2 inhibitor, dapagliflozin, on long term CKD outcomes is the subject of a secondary analysis of the Dapagliflozin Effect on Cardiovascular Events –Thrombolysis In Myocardial Infarction 58 (DECLARE-TIMI 58) trial, recently published in Lancet Diabetes and Endocrinology (5).
Source: Kidney International - Category: Urology & Nephrology Authors: Tania Salehi, P. Toby Coates Tags: Nephrology Digest Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Attack | Invokana | SGLT2 Inhibitors | Sodium | Urology & Nephrology